132 related articles for article (PubMed ID: 9683372)
1. Potentiation of cisplatin activity by the bioreductive agent tirapazamine.
Siemann DW; Hinchman CA
Radiother Oncol; 1998 May; 47(2):215-20. PubMed ID: 9683372
[TBL] [Abstract][Full Text] [Related]
2. The in situ tumour response to combinations of cyclophosphamide and tirapazamine.
Siemann DW
Br J Cancer Suppl; 1996 Jul; 27():S65-9. PubMed ID: 8763849
[TBL] [Abstract][Full Text] [Related]
3. Synergistic enhancement of the antitumor effect of taxol by the bioreductive compound NLCQ-1, in vivo: comparison with tirapazamine.
Papadopoulou MV; Ji M; Bloomer WD
Oncol Res; 2002; 13(1):47-54. PubMed ID: 12201674
[TBL] [Abstract][Full Text] [Related]
4. Effects of bioreductive agents, tirapazamine and mitomycin C, on quiescent cell populations in solid tumors, evaluated by micronucleus assay.
Masunaga S; Ono K; Hori H; Shibata T; Suzuki M; Kinashi Y; Takagaki M; Akaboshi M
Jpn J Cancer Res; 1997 Sep; 88(9):907-14. PubMed ID: 9369940
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine.
Friery OP; Gallagher R; Murray MM; Hughes CM; Galligan ES; McIntyre IA; Patterson LH; Hirst DG; McKeown SR
Br J Cancer; 2000 Apr; 82(8):1469-73. PubMed ID: 10780528
[TBL] [Abstract][Full Text] [Related]
6. Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid.
Cliffe S; Taylor ML; Rutland M; Baguley BC; Hill RP; Wilson WR
Int J Radiat Oncol Biol Phys; 1994 May; 29(2):373-7. PubMed ID: 8195036
[TBL] [Abstract][Full Text] [Related]
7. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine.
Papadopoulou MV; Ji M; Rao MK; Bloomer WD
Oncol Res; 2001; 12(8):325-33. PubMed ID: 11589303
[TBL] [Abstract][Full Text] [Related]
8. Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice.
Papadopoulou MV; Ji M; Bloomer WD
Cancer Chemother Pharmacol; 2001 Aug; 48(2):160-8. PubMed ID: 11561782
[TBL] [Abstract][Full Text] [Related]
9. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin.
Dorie MJ; Brown JM
Cancer Res; 1993 Oct; 53(19):4633-6. PubMed ID: 8402639
[TBL] [Abstract][Full Text] [Related]
10. Tirapazamine-cisplatin: the synergy.
Gatzemeier U; Rodriguez G; Treat J; Miller V; von Roemeling R; Viallet J; Rey A
Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):15-7. PubMed ID: 9647615
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial.
Graham MA; Senan S; Robin H; Eckhardt N; Lendrem D; Hincks J; Greenslade D; Rampling R; Kaye SB; von Roemeling R; Workman P
Cancer Chemother Pharmacol; 1997; 40(1):1-10. PubMed ID: 9137522
[TBL] [Abstract][Full Text] [Related]
12. Tirapazamine: a new drug producing tumor specific enhancement of platinum-based chemotherapy in non-small-cell lung cancer.
Wouters BG; Wang LH; Brown JM
Ann Oncol; 1999; 10 Suppl 5():S29-33. PubMed ID: 10582136
[TBL] [Abstract][Full Text] [Related]
13. Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine.
Brown JM
Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):12-4. PubMed ID: 9647614
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of the toxicity of tirapazamine plus cisplatin in a mouse tumor model].
Adam M; Ottenjann S; Künzel G; Busch R; Erhardt W; Nieder C; Molls M
Strahlenther Onkol; 2006 Apr; 182(4):231-9. PubMed ID: 16622625
[TBL] [Abstract][Full Text] [Related]
15. Tirapazamine: from bench to clinical trials.
Marcu L; Olver I
Curr Clin Pharmacol; 2006 Jan; 1(1):71-9. PubMed ID: 18666379
[TBL] [Abstract][Full Text] [Related]
16. The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N.
Gallagher R; Hughes CM; Murray MM; Friery OP; Patterson LH; Hirst DG; McKeown SR
Br J Cancer; 2001 Aug; 85(4):625-9. PubMed ID: 11506506
[TBL] [Abstract][Full Text] [Related]
17. Combined effects of tirapazamine and mild hyperthermia on anti-angiogenic agent (TNP-470) treated tumors-reference to the effect on intratumor quiescent cells.
Masunaga S; Ono K; Nishimura Y; Kanamori S; Saga T; Suzuki M; Kinashi Y; Takagaki M; Kasai S; Nagasawa H; Uto Y; Hori H
Int J Radiat Oncol Biol Phys; 2000 Jun; 47(3):799-807. PubMed ID: 10837967
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors.
Johnson CA; Kilpatrick D; von Roemeling R; Langer C; Graham MA; Greenslade D; Kennedy G; Keenan E; O'Dwyer PJ
J Clin Oncol; 1997 Feb; 15(2):773-80. PubMed ID: 9053504
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma.
Holden SA; Teicher BA; Ara G; Herman TS; Coleman CN
J Natl Cancer Inst; 1992 Feb; 84(3):187-93. PubMed ID: 1542129
[TBL] [Abstract][Full Text] [Related]
20. The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours.
Lartigau E; Guichard M
Br J Cancer; 1996 Jun; 73(12):1480-5. PubMed ID: 8664116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
